Abcam, ab305032, Anti-GRIN3A antibody [EPR25287-73] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NR3A antibody. Carrier free. Suitable for IHC-P and reacts with Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25287-73,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The NR3A protein also known as GluN3A is a subunit of the N-methyl-D-aspartate (NMDA) receptor an important glutamate receptor in the brain. It has a molecular weight of about 120 kDa. NR3A is expressed in various regions of the central nervous system but it is mostly present during early brain development. This subunit forms part of a receptor channel complex that is critical for synaptic plasticity and neurotransmission. NR3A regulates ion flow across the neuronal membrane in response to neurotransmitter binding modulating calcium permeability and excitability of neurons.
Biological function summary
NR3A serves to shape synaptic development and fine-tune signaling during early brain maturation. The NR3A subunit exists in a complex with other NMDA receptor subunits including NR1 and NR2 affecting receptor function by decreasing calcium influx when present. It can influence synaptic pruning and circuit formation which are essential processes in neurodevelopment. The presence of NR3A in the NMDA receptor decreases the receptor's calcium permeability altering the excitatory post-synaptic potential.
Pathways
Involvement in synaptic plasticity pathways connects NR3A to processes such as long-term potentiation (LTP) and long-term depression (LTD) which are important for learning and memory. The NMDA receptor containing NR3A plays a regulatory role in these pathways by mediating calcium entry into cells affecting downstream signaling events. NR3A has interactions with proteins such as CaMKII and PSD-95 which are key components in signaling cascades linked to synaptic strengthening and synapse stability.
NR3A has associations with neurodevelopmental disorders and neurodegenerative diseases. It is implicated in conditions such as schizophrenia where altered NR3A expression or function may contribute to cognitive deficits. Changes in NR3A levels relate to disruptions in NMDA receptor-mediated neurotransmission and could be linked to abnormal synaptic connectivity. Additionally NR3A might connect to Alzheimer's disease through pathways involving altered NMDA receptor activity where NR1 and NR2 subunits also play critical roles.